Earnings Feed
Start Free
REGENERON PHARMACEUTICALS, INC.·4

Jan 25, 4:17 PM ET

Landry Robert E 4

4 · REGENERON PHARMACEUTICALS, INC. · Filed Jan 25, 2024

Insider Transaction Report

Form 4
Period: 2024-01-23
REGENERON PHARMACEUTICALS, INC.REGN
Landry Robert E
SVP Fin, Dep CFO
Transactions
  • Tax Payment

    Common Stock

    2024-01-23$948.50/sh−776$736,036→ 23,308 total
  • Exercise/Conversion

    Common Stock

    2024-01-24$378.98/sh+500$189,490→ 23,808 total
  • Tax Payment

    Common Stock

    2024-01-24$951.26/sh−352$334,844→ 23,456 total
  • Exercise/Conversion

    Non-Qualified Stock Option (right to buy)

    2024-01-23−1,100→ 13,087 total
    Exercise: $378.98Exp: 2027-12-12→ Common Stock (1,100 underlying)
  • Exercise/Conversion

    Non-Qualified Stock Option (right to buy)

    2024-01-24−500→ 12,587 total
    Exercise: $378.98Exp: 2027-12-12→ Common Stock (500 underlying)
  • Exercise/Conversion

    Common Stock

    2024-01-23$378.98/sh+1,100$416,878→ 24,084 total
Holdings

  • Common Stock

    (indirect: By 401(k))
    270
Footnotes (1)
  • [F1]The stock option award vests in four equal annual installments, commencing one year after the date of grant.

Documents

1 file
  • 4
    edgardoc.xmlPrimary

    PRIMARY DOCUMENT